Abstract Body

Despite the success of existing antiretroviral therapy (ART) in controlling human immunodeficiency virus type 1 (HIV-1) infection, treatment requires life-long adherence to medicines. ART compliance can be compromised by frequency of dosing, and long acting formulations could potentially improve patient adherence. However, the hydrophilic nature of nucleoside reverse transcriptase inhibitors (NRTI) limits their transformation into long acting formulations.  To this end, tenofovir (TFV), a NRTI, was modified into two different lipophilic prodrugs (M1TFV and M2TFV) to extend the apparent drug half-life, improve potency and facilitate access to viral replication sites. 

TFV was modified and formulated into long acting lipid nanocrystals by high-pressure homogenization. The created TFV prodrugs were purified by silica column chromatography and characterized by NMR and FTIR. Nanoparticles were produced by high-pressure homogenization (NM1TFV, NM2TFV). Human monocyte derived macrophages (MDM) and CEM-ss T-cells were used as a biological platform to measure drug uptake and retention. Drug levels were quantitated in cell lysates by UPLC-TUV. After MDM treatment with 100 µM NM1TFV cells were challenged with HIV-ADA at a MOI of 0.1 at five day intervals for one month. Culture fluids were assayed for reverse transcriptase activity and cell-based HIV-p24 antigens recorded by immunohistochemistry. To assess the pharmacokinetic (PK) profile of these TFV prodrug formulations, male Sprague Dawley rats were injected with 75 mg/kg TFV equivalents of NM1TFV, NM2TFV, or TAF. Plasma, blood and peripheral blood mononuclear cells were collected weekly after injection. At the end of the four-week study, organs and tissues were collected for analysis of prodrug, parent drug, and triphosphate levels.

Prodrug modifications enhanced drug uptake compared to tenofovir alefenimde fumarate (TAF) in both MDM and CEM-ss T-cells. M1TFV and M2TFV nanoparticles showed sustained prodrug levels in MDM for 30 and 15 days respectively; whereas TAF was eliminated within a day. In cellular efficacy studies, single treatment of ND1TFV restricted viral replication for 30 days. Analysis of the preliminary rat PK study is currently ongoing.

Long acting TFV formulations were developed and preliminary studies showed enhanced cellular uptake and sustained anti-HIV activity in vitro single dosing when compared against TAF. These results are promising for development of a long-acting TFV for HIV treatment and prevention.